Vidal健康与血清研究所在印度启动了2025年10月1日的数字HPV疫苗方案,促进获得疫苗和预防宫颈癌。 Vidal Health and Serum Institute launch digital HPV vaccine program in India Oct. 1, 2025, boosting access and cervical cancer prevention.

Vidal Health, Bajaj Finserv子公司,与印度血清研究所合作,从2025年10月1日起在印度扩大获得HPV疫苗的渠道。 Vidal Health, a Bajaj Finserv subsidiary, has partnered with Serum Institute of India to expand access to the HPV vaccine in India starting October 1, 2025. 通过数字平台,用户可以预约预约、登记、接受无现金疫苗接种,并在没有书面文件的情况下获得认证。 Through a digital platform, users can book appointments, register, receive cashless vaccinations, and get certification with no paperwork. 该倡议提供自动提醒、合规跟踪和无缝护理连续性,消除中介,改善获得高质量疫苗的机会。 The initiative offers automated reminders, adherence tracking, and seamless care continuity, eliminating intermediaries and improving access to high-quality vaccines. 该方案通过利用技术、提高认识以及有利的工作场所和诊所接种疫苗,支持国家预防宫颈癌的努力。 The program supports national cervical cancer prevention efforts by leveraging technology, increasing awareness, and enabling workplace and clinic vaccinations.